DCGI orders withdrawal of AstraZeneca’s Olaparib tablets for gBRCA mutation and advanced ovarian cancer due to potential adverse effects. The drug was approved in 2018 for adult patients with ovarian cancer and certain breast cancers.

โ€‹DCGI orders withdrawal of AstraZeneca’s Olaparib tablets for gBRCA mutation and advanced ovarian cancer due to potential adverse effects. The drug was approved in 2018 for adult patients with ovarian cancer and certain breast cancers.ย 

โ€‹ย 



Leave a Reply

Your email address will not be published. Required fields are marked *

Search

About

Lorem Ipsum has been the industrys standard dummy text ever since the 1500s, when an unknown prmontserrat took a galley of type and scrambled it to make a type specimen book.

Lorem Ipsum has been the industrys standard dummy text ever since the 1500s, when an unknown prmontserrat took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged.

Gallery